Clinical trial Recruiting at 25 sites Phase2; Phase3 Interventional Ages 40 to 80

Evaluating BHV-8000 for treating early Parkinson's disease in adults

Official title: A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Run by Biohaven Pharmaceuticals, Inc. · NCT06976268 · Data updated 2026-11-12

This study is testing a new treatment called BHV-8000 to see if it can help adults with early Parkinson's disease feel better.

More Parkinson Disease trials

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages40 Years to 80 Years
SexAll
Enrollment550 (estimated)
SponsorBiohaven Pharmaceuticals, Inc.
Industry-sponsored
Locations25 sites (Birmingham, Alabama and 24 other locations)
StatusRecruiting
StartedMay 28, 2025
Main results expectedAugust 2027
Study endsSeptember 2028
Registry record updatedOctober 22, 2026
Trial IDNCT06976268 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 40 to 85 who have been diagnosed with idiopathic Parkinson's disease within the last two years.

Probably not a fit

Patients with Parkinsonian syndromes other than idiopathic Parkinson's disease or those with significant CNS diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy, safety, and tolerability of BHV-8000 in adults diagnosed with early Parkinson's disease. Participants aged 40 to 85 will be enrolled if they meet specific diagnostic criteria for probable Parkinson's disease and have had symptoms for no more than two years. The study will involve administering either BHV-8000 or a placebo to evaluate its effects on the condition. The goal is to determine if this treatment can improve patient outcomes in the early stages of Parkinson's disease.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with early Parkinson's disease, potentially improving their quality of life.

How similar studies have gone: While there have been studies on various treatments for Parkinson's disease, the specific approach with BHV-8000 is novel and has not been extensively tested in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

* Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent.
* Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.
* Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit

Key Exclusion Criteria:

* Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.
* Diagnosis of clinically significant central nervous system (CNS) disease other than PD.
* Participants who are current smokers (defined as smoking \[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\] )
* Treatment with PD medication(s)
* Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.

Where it's running

  • Site-049
    Birmingham, Alabama, United States
    Recruiting
  • Site-079
    Sun City, Arizona, United States
    Recruiting
  • Site-003
    Irvine, California, United States
    Recruiting
  • Site-041
    Los Angeles, California, United States
    Recruiting
  • Site-025
    Aurora, Colorado, United States
    Recruiting
  • Site-031
    Farmington, Connecticut, United States
    Recruiting
Show 19 more locations
  • Site-028
    New Haven, Connecticut, United States
    Recruiting
  • Site-038
    Atlantis, Florida, United States
    Recruiting
  • Site-017
    Boca Raton, Florida, United States
    Recruiting
  • Site-051
    Maitland, Florida, United States
    Recruiting
  • Site-027
    Chicago, Illinois, United States
    Recruiting
  • Site-029
    Kansas City, Kansas, United States
    Recruiting
  • Site-071
    Boston, Massachusetts, United States
    Recruiting
  • Site-004
    Foxborough, Massachusetts, United States
    Recruiting
  • Site-015
    Farmington Hills, Michigan, United States
    Recruiting
  • Site-044
    Chesterfield, Missouri, United States
    Recruiting
  • Site-006
    Albany, New York, United States
    Recruiting
  • Site-005
    New York, New York, United States
    Recruiting
  • Site-082
    Cleveland, Ohio, United States
    Recruiting
  • Site-091
    Portland, Oregon, United States
    Recruiting
  • Site-043
    Round Rock, Texas, United States
    Recruiting
  • Site-009
    Henrico, Virginia, United States
    Recruiting
  • Site-074
    Newport News, Virginia, United States
    Recruiting
  • Site-007
    Bellevue, Washington, United States
    Recruiting
  • Site-019
    Seattle, Washington, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.